WealthTrust Fairport’s Vertex Pharmaceuticals VRTX Stock Holding History

WealthTrust Fairport’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$57K	Hold	311	–	–	0.01%	226
2018 Q4	$52K	Hold	311	–	–	0.01%	221
2018 Q3	$60K	Hold	311	–	–	0.01%	240
2018 Q2	$53K	Hold	311	–	–	0.01%	245
2018 Q1	$51K	Buy	+311	New	+$50.8K	0.01%	237

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WealthTrust Fairport's VRTX Position: Q1 2019 in Review

WealthTrust Fairport held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2019 at 311 shares worth $57K. The position accounts for 0.01% of the portfolio, ranked #226.

WealthTrust Fairport first reported a position in VRTX in Q1 2018 and has held it in 5 quarters since. The position peaked at $60K in Q3 2018. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

WealthTrust Fairport held 311 shares of Vertex Pharmaceuticals worth $57K as of Q1 2019.
WealthTrust Fairport left its Vertex Pharmaceuticals share count unchanged in Q1 2019.
Vertex Pharmaceuticals made up 0.01% of WealthTrust Fairport's portfolio in Q1 2019, its #226 holding.
WealthTrust Fairport first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 5 quarters since.
WealthTrust Fairport's Vertex Pharmaceuticals position peaked at $60K in Q3 2018.
737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on WealthTrust Fairport's 13F filing for Q1 2019, filed 15 May 2019.